Want to join the conversation?
$BIIB 2Q15 Q&A: Meacham of Barclays asked a question about Europe being as big as the US in terms of potential for TECFIDERA. Tony commented that on Europe is mathematically impossible to be as big as US given the differential in pricing and net revenue per patient. Total dynamic is, BIIB has seen good patient growth in Europe.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.